• LY2603618: Chk1 Inhibitor Workflow for DDR Studies

  2026-08-16

  LY2603618 enables mechanism-focused studies of Chk1 inhibition, DNA damage accumulation, and cell-cycle disruption across cancer models. This workflow combines practical dosing guidance with patient-specific assay design inspired by an iPSC-based clinical trial selection platform.

• Removing Pollen Interference in Hazardous Aerosol Detection

  2026-08-15

  Zhang and colleagues developed a fluorescence-data workflow that reduces pollen interference when classifying hazardous bioaerosol components. Combining spectral transformations, especially fast Fourier transform, with random forest classification improved recognition of pathogens and toxins and supports more reliable rapid aerosol monitoring.

• Nonselective β-Blockade Delays HCT Recovery

  2026-08-14

  The reference study shows that nonselective β-adrenergic receptor inhibition can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation (HCT), whereas β1-selective blockade with metoprolol did not produce the same defect. By integrating mouse transplantation experiments with analyses of human HCT cohorts, the work identifies β-blocker selectivity as a clinically relevant variable in post-transplant engraftment.

• Myriocin Workflow for Sphingolipid Research

  2026-08-14

  Myriocin enables direct, experimentally tractable control of de novo sphingolipid biosynthesis for cancer, immunology, and brain-lipid studies. This workflow connects SPT inhibition with dose-response design, spatial lipid imaging, target-engagement assays, and practical troubleshooting.

• Methylprednisolone Sodium Succinate: Research Workflows

  2026-08-13

  Build controlled inflammation, cytokine, ROS, chemotaxis, and apoptosis experiments around a water-compatible synthetic corticosteroid. This guide emphasizes concentration-window mapping, time-course design, translational injury models, and practical troubleshooting for reproducible bench research.

• In Vitro Mammalian Embryonic Dormancy via mTOR Inhibition

  2026-08-13

  This Nature Protocols study translates embryonic diapause into reversible in vitro systems using pharmacological mTOR inhibition in mouse blastocysts, human blastoids, and pluripotent stem cells. Its main contribution is a practical, noninvasive framework for inducing, releasing, and evaluating dormancy while preserving developmental potential, although model-specific validation remains essential.

• MK-0812 Workflows for Gut–Liver Inflammation

  2026-08-12

  This guide translates selective CCR2 blockade into practical whole-blood, monocyte-trafficking, and gut–liver-axis experiments. It combines MK-0812 pharmacology with the TM6SF2–MASH model to help researchers separate monocyte recruitment effects from epithelial, microbial, and lipid-signaling changes.

• Aprotinin for RBC Membrane Research

  2026-08-12

  Aprotinin provides a practical way to separate serine-protease activity from membrane mechanics, fibrinolysis, and inflammatory readouts. This workflow connects bovine pancreatic trypsin inhibitor use with red blood cell membrane studies while highlighting controls, preparation choices, and interpretation limits.

• T0070907: A Mechanistic Probe of PPARγ Signaling

  2026-08-11

  T0070907 is a covalent PPARγ antagonist for dissecting receptor-dependent transcription, adipogenesis inhibition, and cell-cycle responses. This guide connects its molecular pharmacology with the RXRα/PPARγ/NEDD4 axis while emphasizing assay design, controls, and interpretation.

• Flubendazole: A Translational Autophagy Strategy

  2026-08-11

  Flubendazole offers translational researchers a practical chemical entry point for studying autophagy modulation across cancer biology research, neurodegenerative disease models, and metabolic disease hypotheses. This article connects its research-use profile with findings on glutamine metabolism, GDH, SIRT4, and hepatic stellate cell activation while emphasizing assay validation, solubility control, and the limits of cross-domain inference.

• SB 431542: Selective ALK5 Inhibitor Guide

  2026-08-10

  SB 431542 is an ATP-competitive ALK5 inhibitor that suppresses TGF-β receptor signaling and Smad2 pathway activation. Its reported biochemical potency, receptor selectivity, glioma assay activity, and breast cancer pathway evidence support use as a research tool rather than as a therapeutic agent.

• NF 340: Mapping P2Y11 in Cancer Signaling

  2026-08-09

  NF 340 offers translational researchers a receptor-level way to interrogate P2Y11 signaling, connect QPRT metabolism with breast cancer invasion, and build more rigorous immunology and inflammation studies.

• QPRT, P2Y11 Signaling, and Breast Cancer Invasion

  2026-08-08

  Liu et al. linked elevated quinolinate phosphoribosyltransferase (QPRT) to breast cancer cell migration and invasion through a purinergic signaling route that converges on myosin light chain phosphorylation. The study combines tumor-expression analysis, genetic perturbation, invasion assays, and pathway-directed inhibitors to position QPRT–P2Y11 signaling as a mechanistic model for metabolic control of cancer-cell motility.

• Ruxolitinib phosphate: JAK/STAT Workflows

  2026-08-07

  Ruxolitinib phosphate enables controlled JAK1/JAK2 perturbation across cytokine-response, autoimmune, and tumor-cell assays. This guide translates the compound’s reported ATC mechanism into practical dosing, mitochondrial-readout, and troubleshooting workflows.

• Enhancing Immunodetection with HRP Goat Anti-Mouse IgG (H+L)

  2026-08-07

  This article addresses key workflow challenges in cell viability, proliferation, and cytotoxicity assays, highlighting how HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) from APExBIO delivers reliable, reproducible signal amplification. Scenario-driven analysis demonstrates the reagent’s evidence-backed advantages in ELISA, Western blot, and IHC protocols, optimizing sensitivity and data integrity for biomedical researchers.

449 records 1/30 page Next 12345 下5页 Last page